Industry News
Obesity Linked To Worse Outcomes In Early Breast Cancer Treatment
Dec 08, 2011
Obesity is associated with worse outcomes overall in early-stage breast cancer, researchers reported at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011. Obesity was linked to shorter time to recurrence (TTR), disease-free survival (DFS) and overall survival (OS)... Read More
Chemo Combo Kills Resistant Ovarian Cancer Cells
Dec 08, 2011
Two drugs never used together before in treating ovarian cancer killed 70% of cells already resistant to commonly used chemotherapy compounds, concludes a new study published online recently in Gynecologic Oncology... Read More
The Importance Of Echocardiography To Evaluate Cardio Toxicity In Cancer Patients: EUROECHO 2011
Dec 08, 2011
One study presented at the meeting, which is being held in Budapest, Hungary, 7 to 10 December, reports on an initiative using echocardiography to document early warning signs of adverse effects from trastuzumab (Herceptin ®)¹, while the other uses echocardiography to evaluate the protective role of ACE inhibitors and statins on the hearts of cancer patients²... Read More
Breast Cancer Mortality Higher In Hispanic Women
Dec 08, 2011
Hispanic women are more likely to die from breast cancer than non-Hispanic white women, according to research presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011. "This difference may be associated with a tumor phenotype that is less responsive to chemotherapy," said Kathy B. Baumgartner, Ph.D... Read More
Dual HER2 Blockade Significantly Extends Progression-Free Survival
Dec 08, 2011
Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who received the combination therapy with placebo... Read More
Exemestane Plus Everolimus Increased Progression-Free Survival For Women With Metastatic Breast Cancer
Dec 08, 2011
Everolimus in combination with exemestane has shown promise for the treatment of breast cancer. "For postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer, the addition of everolimus to exemestane markedly improves the duration of disease control," said Gabriel N. Hortobagyi, M.D... Read More
Addition Of Bevacizumab To Conventional Therapy Improved Progression-Free Survival In HER2-Positive Breast Cancer
Dec 08, 2011
Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in HER2-positive breast cancer, despite findings from an investigator assessment that the improvement was present but statistically non-significant. Luca Gianni, M.D... Read More
Combination Of Everolimus And Exemestane Improves Progression-Free Survival For Women With Metastatic Breast Cancer
Dec 08, 2011
In an international Phase III randomized study, everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve progression-free survival, according to research from The University of Texas MD Anderson Cancer Center... Read More
New Protocols Improve Detection Of MicroRNAs For Diagnosis
Dec 08, 2011
MicroRNAs (miRNAs) that regulate processes including fertilization, development, and aging show promise as biomarkers of disease. They can be collected from routinely collected fluids such as blood, saliva, and urine. However, a number of factors can interfere with the accuracy of miRNA tests... Read More
TAU Develops Tumor Destruction Method That Also Creates Immunity
Dec 08, 2011
Even when surgical tumor removal is combined with a heavy dose of chemotherapy or radiation, there's no guarantee that the cancer will not return. Now researchers at Tel Aviv University are strengthening the odds in favor of permanent tumor destruction - and an immunity to the cancer's return - with a new method of tumor removal... Read More
Previous Page Next Page